ST 段抬高心肌梗死靶血管长病变急诊介入治疗的安全性及疗效分析

目的:探讨ST段抬高急性心肌梗死(ST-elevation myocardial infarction,STEMI)患者靶血管长病变(病变>25 mm)急诊经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗的临床疗效及安全性。方法:回顾性收集2009年1月-2010年6月因STEMI就诊于沈阳军区总医院并急诊行PCI处理的患者442例,以靶病变长度分为两组,即≤25 mm为短病变组(n=235)和>25mm为长病变组(n=207),均急诊行PCI治疗,分析和比较两组患者术前的基线资料、术中资料及并发症的发生情况、辅助措施(临时起搏、IABP、血栓抽吸装置)应用情况,术后30天、2年电话或临床随访,记录主要不良心血管事件(major adverse cardiac events,MACE)的发生情况。结果:与短病变组比较,长病变组吸烟者更多(81.6%vs 62.6%,P=0.000);以三支病变偏多(34.8%vs 24.7%,P=0.037);多枚支架使用率更高(1.47±0.63 vs 1.04±0.28,P=0.000),平均支架总长度显著增加(29.80±7.02 mm vs 22.95±5.58mm,P=0.000),手术成功率、术中并发症及辅助措施应用情况比较差异无统计学意义(P>0.05),30天及2年随访MACE的发生率比较差异无统计学意义(P>0.05)。结论:与急诊PCI治疗的STEMI短病变患者对比,长病变患者虽然病变复杂,多枚支架使用率高,平均支架总长度增加,但术中并发症、30天、2年内MACE与短病变患者相当,提示在以药物洗脱支架为主的介入治疗时代,急诊PCI处理STEMI靶血管长病变具有良好的疗效及安全性。     

Barriers to Promoting Eco‐Industrial Parks Development in China

For at least the past two decades, eco‐industrial parks (EIPs) have been promoted as policy and commercial instruments for achieving industrial sustainable development. Yet, few EIPs have seen successful operational implementation, especially if they begin as standard industrial parks. Rapid economic growth, commensurate with increasing environmental damage in China, has resulted in officials’ further pursuing EIP policy as a significant element of the broader circular economy and ecological modernization efforts. This article examines the barriers for EIP development from industrial park senior manager perspectives. Using resource dependence theory and the resource‐based view as theoretical lenses, we investigate the external and internal barriers for EIP development in 51 Chinese industrial parks. A number of barriers are identified and grouped through a factor analysis. Cluster analysis is utilized to help categorize and evaluate the perceived levels of barriers and hardships experienced by various senior officials that manage the EIPs. It is found that few respondents encounter no significant barriers. Barriers related to technological development and capacity building are the most prevalent. These results highlight the relative importance of various activities that may be necessary by policy makers and other stakeholders to overcome the barriers. For example, cooperation in developing technological solutions for EIPs seems to be a major thrust that should be pursued by EIP development stakeholders. Other policy and managerial insights based on the general findings of this study are also presented.     

三种粘结剂用于纵折牙粘结的微渗漏研究

目的观察三种粘结材料的封闭性能,为折裂牙选择合适的粘结材料提供试验依据。方法选用健康前磨牙30颗,随机分为3组,制备成后牙纵折模型,分别用Clearfil SE Bond／AP—X（A组）、Super—Bond C＆B（B组）,Single Bond／F2000 Cmpomer（C组）进行粘结,在0．5％亚甲基蓝溶液中染色72h后,在电镜下观察染料渗透深度。结果扫描电镜下观察各组标本的粘结界面均有染料渗入,经单因素方差分析,A组与B组、C组有显著性差异,B组与C组之间无显著性差异。结论Clearfil SE Bond的封闭性能优于其它两组,但三种粘结剂均无法避免微渗漏的发生。     

穿心莲内酯抗铜绿假单胞菌生物被膜及与阿奇霉素协同抗菌作用

目的研究穿心莲内酯抗铜绿假单胞菌生物被膜及与阿奇霉素协同抗菌作用。方法微量倍比稀释法测定穿心莲内酯对铜绿假单胞菌的最小抑菌浓度（MIC）,棋盘稀释法测定穿心莲内酯和阿奇霉素协同抗菌作用,MTT法测定穿心莲内酯对铜绿假单胞菌生物被膜的最小抑膜浓度（SMIC）,显微镜下观察药物对生物膜形态的影响。结果穿心莲内酯对铜绿假单胞菌的MIC 50μg/mL,和阿奇霉素有协同抗菌作用。穿心莲内酯对铜绿假单胞菌生物被膜的SMIC501天25μg/mL、3天25μg/mL、7天50μg/mL;SMIC801天50μg/mL、3天50μg/mL、7天100μg/mL,形态观察提示穿心莲内酯SMIC80浓度对铜绿假单胞菌生物被膜的抑制作用明显。结论穿心莲内酯具有抗铜绿假单胞菌生物被膜作用,对阿奇霉素也有协同抗菌作用。     

野生樱桃李扦插繁殖研究初报

以野生樱桃李的新梢为试材,采用不同的扦插基质、不同浓度的吲哚丁酸(IBA)、萘乙酸(NAA)和生根粉(ABR)对野生樱桃李插条进行扦插生根试验.试验结果表明,野生樱桃李在蛭石与河沙中的生根效果好于锯末中的生根,蛭石与河沙中插条的生根率接近,生根率分别达到了40.0%、39.6%,因此都可作为野生樱桃李扦插的适宜基质.适宜浓度NAA、IBA可以促进野生樱桃李的生根,浓度过低,达不到促进效果,浓度过高,则可能抑制了插条的生根,相比而言,效果NAA较好,其适宜处理浓度为200 mg/L.但各种激素处理后,无论生根率高低,对根的生长具有促进作用.     

中国大陆若干群体的黑果蝇的线粒体DNA多态性研究

本文研究了果蝇Ｄ．ｖｉｒｉｌｉｓ种群Ｄ．ｖｉｒｉｌｉｓ线粒体ＤＮＡ（ｍｉｔｏｃｈｏｎｄｒｉａｌＤＮＡ,ｍｔＤＮＡ）的多态性。用９种限制性内切酶ＸｂａⅠ,ＥｃｏＲⅠ,ＰｓｔⅠ,ＨｉｎｄⅢ,ＢｇｌⅡ,ＳａｃⅠ,ＳｃａⅠ,ＥｃｏＲＶ和ＰｕｖⅡ,对青岛、南京、上海、宁波与泉州５个Ｄ．ｖｉｒｉｌｉｓ群体的ｍｔＤＮＡ进行了限制性片段长度多态性（ｒｅｓｔｒｉｃｔｉｏｎｆｒａｇｍｅｎｔｓｌｅｎｇｔｈｐｏｌｙｍｏｒｐｈｉｓｍ,ＲＦＬＰ）的研究。在５群体中,发现５种不同的酶切图谱,它们彼此之间的遗传差异π为０．４６％－１．７６％,群体内遗传差异πｉｊ为０．００％－０．３３％,群体间的差异ｄｘｙ,为０．００％－０．８２％。分布于中国大陆的Ｄ．ｖｉｒｉｌｉｓ的群体间遗传差异在总遗传差异中所占比例γｓｔ值为２４．６２％。我们发现,Ｄ．ｖｉｒｉｌｉｓ的栖息环境对ｍｔＤＮＡ的遗传变异有十分明显的影响,而不同地理纬度的群体之间其遗传距离并无倾群（ｃｌｉｎｅ）表现。     

中国葫芦科1新记录种——厚叶棒锤瓜

报道了葫芦科厚叶棒锤瓜[Neoalsomitra sarcophylla(Wall.)Hutch.]在中国的分布新记录。该物种形态上与N.balansae(Gagnep.)Hutch.近似,但蒴果长3~4cm;种子长6~7mm,宽3~4mm,两端呈短角状。本研究利用DNA条形码技术对该物种进行测序,获得matK、rbcL、psbA-trnH 3个基因序列。应用Blast法为该物种的分类处理提供佐证。凭证标本存放于广西药用植物园标本馆(GXMG)。     

萘对川西亚高山森林土壤微生物量、丰度和磷脂脂肪酸的影响

萘作为土壤动物化学抑制剂已在土壤动物生态功能的研究中广泛使用,但其非目标效应使其应用仍存在很大的不确定性。为了解在亚高山森林土壤应用萘抑制土壤动物群落的非目标效应,以川西亚高山森林土壤为研究对象,采用微缩实验研究了土壤微生物生物量、丰度和磷脂脂肪酸对萘胁迫的短期响应。结果表明,萘处理和对照的土壤微生物生物量碳(MBC)、真菌丰度以及细菌、真菌、革兰氏阳性菌(G~+)和革兰氏阴性菌(G~-)PLFAs含量在整个培养期间表现为降低的变化趋势,二者的土壤微生物生物量碳和G~+PLFAs含量以培养52d最低,细菌、真菌和G~-PLFAs含量以培养的45d最低。萘处理和对照的微生物生物量氮(MBN)含量表现出先升高后降低的动态,微生物生物量碳氮比(MBC/MBN)则表现为相反趋势。对照的真菌/细菌PLFAs比值呈现先升高后降低的动态,以培养的17d最高,但萘处理的真菌/细菌PLFAs比值无明显变化规律;萘处理的G~+/G~-PLFAs比值表现为降低的变化趋势,对照的G~+/G~-PLFAs比值表现为先降低后升高的趋势。萘处理仅显著影响了G~+/G~-PLFAs比值,但萘处理和采样时间的交互作用显著影响MBC/MBN、细菌丰度、真菌/细菌丰度比以及细菌、真菌的PLFAs含量、真菌/细菌PLFAs比值、G~+/G~-PLFAs比值。萘作为土壤动物抑制剂对川西亚高山森林土壤微生物群落的非目标效应具有时间变异性。     

Epac‐2 ameliorates spontaneous colitis in Il‐10 −/− mice by protecting the intestinal barrier and suppressing NF‐κB/MAPK signalling

Intestinal barrier dysfunction and intestinal inflammation interact in the progression of Crohn''s disease (CD). A recent study indicated that Epac‐2 protected the intestinal barrier and had anti‐inflammatory effects. The present study examined the function of Epac‐2 in CD‐like colitis. Interleukin‐10 gene knockout (Il‐10 ^−/−) mice exhibit significant spontaneous enteritis and were used as the CD model. These mice were treated with Epac‐2 agonists (Me‐cAMP) or Epac‐2 antagonists (HJC‐0350) or were fed normally (control), and colitis and intestinal barrier structure and function were compared. A Caco‐2 and RAW 264.7 cell co‐culture system were used to analyse the effects of Epac‐2 on the cross‐talk between intestinal epithelial cells and inflammatory cells. Epac‐2 activation significantly ameliorated colitis in mice, which was indicated by reductions in the colitis inflammation score, the expression of inflammatory factors and intestinal permeability. Epac‐2 activation also decreased Caco‐2 cell permeability in an LPS‐induced cell co‐culture system. Epac‐2 activation significantly suppressed nuclear factor (NF)‐κB/mitogen‐activated protein kinase (MAPK) signalling in vivo and in vitro. Epac‐2 may be a therapeutic target for CD based on its anti‐inflammatory functions and protective effects on the intestinal barrier.